Clinical Trial Update: Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose [Phase 4]

View source ↗

Summary

Phase 4 trial assessing safety and immunogenicity of Adacel booster given 10 years after prior dose in adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• ADACEL (Tdap vaccine (tetanus, diphtheria and acellular pertussis vaccine))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Tetanus, Diphtheria | Phase 4 | Status: COMPLETED | Results posted: 2017-10-09